
BioAge Labs (BIOA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
2.4M
Operating Income
-24.8M
-1,026.99%
Net Income
-21.6M
-893.99%
EPS (Diluted)
$-0.60
Balance Sheet Metrics
Total Assets
343.8M
Total Liabilities
30.7M
Shareholders Equity
313.2M
Debt to Equity
0.10
Cash Flow Metrics
Operating Cash Flow
-9.2M
Free Cash Flow
-17.8M
Revenue & Profitability Trend
BioAge Labs Income Statement From 2022 to 2024
Metric | 2024 | 2023 | 2022 |
---|---|---|---|
Revenue | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - |
Gross Profit | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||
Research & Development | 59.0M | 33.9M | 30.5M |
Selling, General & Administrative | 19.2M | 14.5M | 9.4M |
Other Operating Expenses | - | - | - |
Total Operating Expenses | 78.2M | 48.4M | 40.0M |
Operating Income | -78.2M | -48.4M | -40.0M |
Operating Margin % | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||
Interest Income | 9.6M | 2.4M | 465.0K |
Interest Expense | 2.4M | 7.8M | 241.0K |
Other Non-Operating Income | -177.0K | -10.1M | 23.0K |
Pre-tax Income | -71.1M | -63.9M | -39.7M |
Income Tax | - | - | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% |
Net Income | -71.1M | -63.9M | -39.7M |
Net Margin % | 0.0% | 0.0% | 0.0% |
Key Metrics | |||
EBITDA | -68.4M | -45.8M | -39.4M |
EPS (Basic) | $-6.63 | $-7.34 | $-23.76 |
EPS (Diluted) | $-6.63 | $-7.34 | $-23.76 |
Basic Shares Outstanding | 10726521 | 8704292 | 1671761 |
Diluted Shares Outstanding | 10726521 | 8704292 | 1671761 |
Income Statement Trend
BioAge Labs Balance Sheet From 2022 to 2024
Metric | 2024 | 2023 | 2022 |
---|---|---|---|
Assets | |||
Current Assets | |||
Cash & Equivalents | 354.3M | 21.6M | 27.6M |
Short-term Investments | - | - | - |
Accounts Receivable | - | - | - |
Inventory | - | - | - |
Other Current Assets | 2.8M | 349.0K | 386.0K |
Total Current Assets | 357.1M | 25.3M | 28.0M |
Non-Current Assets | |||
Property, Plant & Equipment | 869.0K | 561.0K | 322.0K |
Goodwill | - | - | - |
Intangible Assets | - | - | - |
Long-term Investments | - | - | - |
Other Non-Current Assets | 240.0K | - | 25.0K |
Total Non-Current Assets | 1.1M | 618.0K | 399.0K |
Total Assets | 358.2M | 25.9M | 28.4M |
Liabilities | |||
Current Liabilities | |||
Accounts Payable | 2.0M | 1.9M | 2.3M |
Short-term Debt | 6.2M | 45.1M | 216.0K |
Current Portion of Long-term Debt | - | - | - |
Other Current Liabilities | 417.0K | 1.4M | 24.0K |
Total Current Liabilities | 27.8M | 58.2M | 5.9M |
Non-Current Liabilities | |||
Long-term Debt | 2.5M | 8.2M | 2.3M |
Deferred Tax Liabilities | - | - | - |
Other Non-Current Liabilities | - | - | - |
Total Non-Current Liabilities | 7.3M | 141.2M | 135.1M |
Total Liabilities | 35.1M | 199.3M | 141.0M |
Equity | |||
Common Stock | 0 | 0 | 0 |
Retained Earnings | -252.8M | -181.7M | -117.8M |
Treasury Stock | - | - | - |
Other Equity | - | - | - |
Total Shareholders Equity | 323.1M | -173.4M | -112.6M |
Key Metrics | |||
Total Debt | 8.7M | 53.3M | 2.5M |
Working Capital | 329.3M | -32.9M | 22.2M |
Balance Sheet Composition
BioAge Labs Cash Flow Statement From 2022 to 2024
Metric | 2024 | 2023 | 2022 |
---|---|---|---|
Operating Activities | |||
Net Income | -71.1M | -63.9M | -39.7M |
Depreciation & Amortization | 167.0K | 162.0K | 129.0K |
Stock-Based Compensation | 7.0M | 3.0M | 2.5M |
Working Capital Changes | 9.0M | 2.9M | 1.3M |
Operating Cash Flow | -54.0M | -51.2M | -35.6M |
Investing Activities | |||
Capital Expenditures | -366.0K | -166.0K | -103.0K |
Acquisitions | - | - | - |
Investment Purchases | 0 | -100.0K | 0 |
Investment Sales | - | - | - |
Investing Cash Flow | -366.0K | -266.0K | -103.0K |
Financing Activities | |||
Share Repurchases | - | - | - |
Dividends Paid | - | - | - |
Debt Issuance | 0 | 12.5M | 2.5M |
Debt Repayment | -6.0M | -1.0M | 0 |
Financing Cash Flow | 380.6M | 34.9M | 2.5M |
Free Cash Flow | -51.9M | -37.5M | -36.3M |
Net Change in Cash | 326.2M | -16.5M | -33.3M |
Cash Flow Trend
BioAge Labs Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.89
Forward P/E
-2.08
Price to Book
0.72
Price to Sales
54.57
PEG Ratio
-2.08
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-1,026.99%
Return on Equity
-35.88%
Return on Assets
-23.46%
Financial Health
Current Ratio
13.21
Debt to Equity
2.97
Per Share Data
EPS (TTM)
$-7.38
Book Value per Share
$8.22
Revenue per Share
$0.14
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
bioa | 212.2M | -0.89 | 0.72 | -35.88% | 0.00% | 2.97 |
Haleon Plc - ADR | 41.7B | 19.93 | 5.08 | 9.38% | 13.81% | 53.41 |
United Therapeutics | 19.3B | 16.92 | 2.68 | 19.30% | 40.36% | 0.00 |
Ironwood | 230.7M | 92.69 | -0.73 | -0.29% | -2.56% | -1.94 |
Journey Medical | 186.8M | 39.08 | 8.66 | -57.22% | -15.49% | 131.34 |
China SXT | 183.3M | 0.01 | 1.44 | -22.50% | -189.77% | 6.37 |
Financial data is updated regularly. All figures are in the company's reporting currency.